Absolute Bioavailability of Osimertinib in Healthy Adults

• Published in: Clinical pharmacology in drug development Vol. 8; no. 2; pp. 198 - 207
• Main Authors: Vishwanathan, Karthick, So, Karen, Thomas, Karen, Bramley, Alex, English, Stephen, Collier, Jo
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2019
• Subjects: absolute bioavailability; Acrylamides - administration & dosage; Acrylamides - pharmacokinetics; Administration, Intravenous; Administration, Oral; Adult; Aniline Compounds - administration & dosage; Aniline Compounds - pharmacokinetics; Bioavailability; Biological Availability; Drug Administration Schedule; Drug therapy; Epidermal growth factor; Female; Healthy Volunteers; Humans; Inhibitor drugs; Male; Mass Spectrometry; microtracer; Middle Aged; Nervous system; non‐small cell lung cancer; osimertinib; pharmacokinetics; Pharmacology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacokinetics; Targeted cancer therapy; Young Adult; non-small cell lung cancer; pharmacokinetics; absolute bioavailability; microtracer; osimertinib

Osimertinib is a third‐generation, central nervous system–active, epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI) selective for EGFR‐TKI sensitizing and T790M resistance mutations. This phase 1, open‐label study (NCT02491944) investigated absolute bioavailability and pharmacoki...